EVE Health Moves Into Commercial Phase With First Dyspro Prescriptions and Libbo Manufacturing Milestone

EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.

EVE Health Group has transitioned from development to early commercialisation in the December 2025 quarter, with first patient prescriptions of Dyspro™ under Australian regulatory pathways and completion of the initial commercial manufacturing run of Libbo™, which is now in national distribution and positioned for near-term prescribing via telehealth and pharmacies. The company strengthened its clinical and patient engagement infrastructure through a national telehealth patient support agreement with hubMed, launch of the Reclaim My Cycle education and research platform for women with period pain, appointment of its first Medical Science Liaison to drive prescriber education, and a $1.1 million capital raising to accelerate the rollout and regulatory progression of both flagship products, leaving it with $0.9 million in cash and signaling growing investor confidence in its commercialisation strategy.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

More about EVE Health Group Limited

EVE Health Group Limited (ASX:EVE) is an Australian life sciences company focused on women’s and men’s health, developing therapeutic products such as Dyspro™, a non-THC cannabinoid-based gummy for dysmenorrhoea and endometriosis, and Libbo™, an oral dissolving film for erectile dysfunction. The company is building integrated manufacturing, distribution, telehealth and pharmacy channels to deliver discreet, convenient access to its treatments across the Australian market.

Average Trading Volume: 422,008

Technical Sentiment Signal: Sell

Current Market Cap: A$5.7M

For detailed information about EVE stock, go to TipRanks’ Stock Analysis page.